News

Under the deal, Organon will obtain global rights to FDA-approved Xaciato, which is intended to treat bacterial vaginosis (BV) in females aged 12 years and above. The vaginal

The company filed the NDA with the Department of Health in the Hong Kong Special Administrative Region. The SG drug is a first-in-class Trop-2 directed antibody-drug conjugate and

The first-in-class bio-HDL mimetic CER-001 works by directly targeting a key underlying metabolic defect of LCAT deficiency. Its anti-inflammatory properties and/or the increase in the Reverse Cholesterol Transport

Under the terms of the deal, Axsome will gain global development, manufacturing commercial, and intellectual property rights to Sunosi, a dual-acting dopamine and norepinephrine reuptake inhibitor, except for

The regulator has also granted paediatric exclusivity for the prescription medication. It was previously approved by the FDA and EU Commission to treat Dravet syndrome-related seizures in children

The combination therapy is intended to treat previously untreated diffuse large B-cell lymphoma (DLBCL), which is the most common form of non-Hodgkin lymphoma (NHL). It is claimed to

The regulatory agency has issued a complete response letter (CRL) to the Biologics License Application (BLA) for sintilimab, which is being co-developed by Innovent Biologics. It recommended the companies

Led by Fidelity Management & Research Company, the financing round has seen participation of new investors that include 3W Partners Capital and Invus, along with existing investors including

Co-led by Leaps by Bayer and Vida Ventures, the round has seen participation from other investors including Catalio Capital Management, The Parker Institute for Cancer Immunotherapy, Erasca Ventures,